Background: Several systematic reviews suggest that intermittent pulmonary tuberculosis (TB)
Introduction
Tuberculosis remains a global public health problem despite the presence of effective TB pharmacotherapy for more than 50 years and the use of vaccines for more than 90 years. The situation is further compounded by the global HIV pandemic which has led to unprecedented increases in both TB incidence and mortality in many areas. Consequently, TB treatment programs are faced with high numbers of TB cases coupled with an increase in unfavourable treatment outcomes among patients undergoing TB treatment. The increasing unfavourable TB treatment outcomes are attributed to poor compliance and adherence to TB treatment secondary to high pill burden, toxicity and adverse reactions as well as treatment inconvenience among other factors [1] .
To mitigate this, intermittent TB treatment regimens have been proposed and evidence suggests that they achieve a similar treatment outcome to daily regimens [2, 3] .
Today, tuberculosis treatment utilizes four key drugs: Ethambutol (E), Isoniazid (H), Rifampicin (R) and Pyrazinamide (Z). Treatment is in two phases; an initial intensive phase (IP) and a continuous phase (CP). In this paper, the phases are indicated by a slash and thus 2HRZE/4RH represents 2 months in the intensive phase and 4 months in the continuous phase with drugs used in each phase denoted as letters. Currently, the World Health Organization (WHO) has recommended the discontinuation of the use of the 8 month treatment regimen that includes only two months of rifampicin treatment (2HRZE/6EH) in preference to a six month treatment regimen with rifampicin in all 6 months (2HRZE/4RH) [4] . In addition, the WHO recommends that this TB treatment regimen (2HRZE/4RH) be administered daily, especially in the IP, except where this daily treatment is not possible. In the latter instance, three times weekly dosing is then allowed [4] .
There is currently no strong evidence that implementation of these daily over intermittent regimens leads to decreases in treatment failure or relapses but they certainly are inconvenient and may lead to non-compliance and subsequent drug resistance. Indeed, the number of multi-drug resistant TB (MDR-TB) cases notified by the 27 high burden countries is on the increase and reached 600,000 cases globally in 2011 [5] . This increase in number of MDR-TB cases requires an investigation into the effectiveness of current TB treatment regimens as well their dosing frequencies. Two systematic reviews [3, 6] undertaken to look into this were limited by methodology with neither looking at all outcome categories nor stratifying treatment intensity 
Data extraction and Quality assessment
Two investigators working independently reviewed all identified and selected studies while resolving data differences through discussion and reaching consensus using a third investigator. We then extracted data from selected studies that met the study criteria on patient population and characteristics, number of patients started on treatment, pre and post treatment bacteriological results (smear and culture), treatment regimens, supervision of treatment (through directly observed therapy (DOT)) and treatment outcomes. The treatment outcomes of interest were in four categories: treatment success, failed, relapsed and defaulted (see definitions below).
Quality of study information was ensured by assessing all included studies using a standardized quality assessment form. The quality assessment scheme was modified from that suggested by Hoy et al [8] which is a validated quality assessment checklist(also see supplementary material online). Once assessed, each study was awarded a univariate summary score from all parameters assessed. The total score for each study was then applied to assign weights for each study included in this meta-analysis. If a study contributed more than one dataset, each had the same quality score assigned. This model of meta-analysis does not assume that quality information quantifies either the magnitude or the direction of bias. The ranking of the studies by quality is used to compute a synthetic bias variance that then increases uncertainty around estimates for lower ranked studies [9] ,.
Outcome definitions and exclusions
WHO tuberculosis case and treatment outcome definitions were used to classify TB cases and to determine treatment outcomes [5, [11] [12] [13] . A new case was defined as a TB patient who has never been on TB treatment before or ever been on TB treatment but for less than one month. A pulmonary TB case was defined as a TB patient with TB disease involving the lung parenchyma.
Regarding treatment outcomes, successfully treated was defined as a combination of completed and cured TB patients. Cure was defined as a patient who was initially bacteriologically positive and who was bacteriologically negative in the last months of treatment and on at least one previous occasion while completed treatment was defined as a patient who completed the standard TB treatment but lacks bacteriological results at the end of treatment. For purposes of this study, a Intermittent vs. daily TB regimens: a meta-analysis Page 5 Copyright © 2015 Marshfield Clinic Health System failure was defined as a TB patient who remains or becomes bacteriologically positive at five or more months of standard TB treatment or who dies during TB treatment. Relapse was defined as a TB patient who becomes bacteriologically positive after being declared cured at end of TB treatment while a defaulter /loss to follow up is a TB patient who interrupted TB treatment for two or more months after being on treatment for more than one month.
Patients who could not be categorised as cured, completed, failed, relapsed or defaulted based on the above definitions or if they were transferred to another reporting unit (health facility or district) during treatment or for whom treatment outcome is unknown, were excluded from analysis.
Data synthesis and analysis
In all the studies, multi-category proportions of successfully treated, failure, relapse and default/loss to follow up were computed as separate categories and pooled simultaneously.
Analyses were done separately for regimens with rifampicin in all phases versus rifampicin in IP only. The primary outcome of interest was the proportions of these four outcomes in those receiving completely intermittent (I/I) or completely daily (D/D) treatment. The secondary outcomes were those for mixed regimens that used daily therapy in one phase and intermittent in the other or regimens that used rifampicin only in the IP.
We used the quality effects model [14] to pool the categorical proportions and report the overall pooled estimate of the various outcome categories. We chose the quality effects model over the conventional random effects model based on the fact that the model incorporates quality of studies in the analysis of the overall intervention efficacy [14] thereby reducing variance of the pooled estimator [9] . This model uses a synthetic bias variance to adjust inverse variance weights and achieves an estimator variance that is smaller than that of the random effects estimator. This synthetic bias variance is computed through the quality assessment and regardless of how subjective the assessment is, so long as it has some information value, the estimator variance decreases. Furthermore, this model also overcomes the coverage problems seen with the random effects estimator for which corrections have been attempted [15] . We nevertheless report conventional results (random effects and fixed effects models, see supplementary material) for comparison. All analyses utilized MetaXL version 2.0 (Epigear International Pty Ltd, Brisbane, Australia; www.epigear.com). We preferred MetaXL in this analysis since it has both an improved Intermittent vs. daily TB regimens: a meta-analysis Page 6 Copyright © 2015 Marshfield Clinic Health System methodology of meta-analysis of multi-category prevalence [7] as well as the ability to execute bias adjusted analyses. By Bias adjustment, we mean that weighting done under this model allows the results of the "big" studies (with less bias) to make a greater contribution to the pooled effect, thus decreasing overall bias of the estimator. In computing the pooled proportions using MetaXL, the double arcsine square root transformation was used to stabilize variance of the proportion and results back transformed for reporting. 95% confidence intervals around pooled estimates were computed as previously reported [7, 10] .
We determined whether heterogeneity (clinical, statistical or methodological) existed among studies that we included in the meta-analysis by drawing up forest plots (figure 2 and 3) to graphically present individual and pooled estimates as well as using the heterogeneity statistics; the Cochran's Q, and I 2 statistic which examine the percentage variation across studies due to heterogeneity [10] . A sensitivity analysis by altering various study selection criteria including study size, year of study, monitoring of therapy and country of origin were computed. We also compared results across different meta-analysis models for outcome comparison. In addition, we looked for publication bias through Doi and funnel plots [10, 16, 17] (Figures 4 and 5 ).
Results

Description of the studies included
We identified 3,179 studies from the three electronic databases of which 806 were duplicates and 2,128 were excluded by title ( Figure 1 ). We therefore retained 245 titles for abstract review from which 127 abstracts were excluded leaving 118 abstracts for review. Upon review of these abstracts as full text, 98 were excluded thereby leaving 20 studies to be included in the metaanalysis. An additional 7 studies were identified through a related citation search of already identified original articles thereby obtaining a total of 27 studies that were included in this metaanalysis.
We obtained 48 data sets from all included studies with 10,624 participants that were enrolled across these studies. Out of the 10,624 participants, 7,611 were on completely daily treatment (28 datasets) and 3,013 on completely intermittent therapy (9 datasets). Of the 10,624 participants, 8,336 were on regimens that contained Rifampicin in both IP and CP (28 datasets) while 2,228 were on regimens that had Rifampicin in IP only (9 datasets). All included studies Intermittent vs. daily TB regimens: a meta-analysis Page 7 Copyright © 2015 Marshfield Clinic Health System involved HIV sero negative adults (except four studies; first one with six, second with 115, third one with 77 and the fourth with 32 HIV sero-positive participants [18] [19] [20] [21] ) with smear positive pulmonary TB (except in one study, 67 out 198 patients were smear negative [22] ). More still, in one study, a third of the 1240 patients included were previously treated [23] . In all these scenarios, ineligible patients could not be excluded by both regimen type and treatment outcome. Again, instead of Rifampicin (R), Rifabutin was used in two of the studies included with a total of 491 participants [24, 25] . Treatment doses were fully supervised in eleven studies [19-21, 23, 26-32 ], supervised as well as self-administered in nine studies [22, 25, [33] [34] [35] [36] [37] [38] , and only self-administered in two [39, 40] while treatment modality was unspecified in five studies [18, 24, [41] [42] [43] .
Pooled Results
Primary outcome -same intensity of dosing throughout a) Intermittent regimens Rifampicin was administered intermittently (I/I) in both phases (twice to thrice weekly) in nine datasets; all of these datasets had a CP of four months [23, 24, 26, 28, 30, 44] . The overall treatment success with this intermittent regimen was 88% [(95% CI: 81-92), failure and relapse rates were 5% (95% CI: 2-9) versus 7% (95% CI: 3-11) and default rate was 0% (95% CI: 0 -2) ( [19, 35, 38, 42, 44] . These regimens had an overall treatment success of 75% (95% CI: 57-91). The failure and relapse rates were 5% (95% CI: 0 -15) and 2% (95% CI: 0-9) but the default rates were 15% (95% CI: 2 -30).
There were two studies' of I/D administration of 6 months [19, 37] . The overall treatment success among these regimens having no Rifampicin in the CP was 81% [(95% CI: 31-100), with a failure and relapse rates of 8% (95% CI: 0-47) versus 5% (95% CI: 0-42) and default rate of 3% (95% CI: 0-36).
There was one study of a D/I therapy that did not use rifampicin in the CP and of six months duration [45] . It reported a treatment success of 74% [(95% CI: 64-84), with a failure and relapse rates of 26% (95% CI: 16-36) versus 0% (95% CI: 0-2) and default rate of 0% (95% CI: 0-2) ( Table   1) .
Sensitivity analysis
Sensitivity analysis was done for the D/D studies by altering selection criteria such as regimen type, treatment duration, dosing frequency, treatment outcome and comparing treatment outcome results across different meta-analysis models. More still, comparisons were made by examining treatment outcomes in relation to study size, year of publication, country where study was conducted as well as wether therapy was monitored or not. No significant differences were observed across treatment outcomes under both quality effect and fixed effect (IVhet) meta-analysis models. For instance, under a quality effects model, the D/D group with rifampicin administered throughout, treatment success among bigger and smaller studies were 90% (95% CI: 82-96) versus 91% (95% CI: 81-99). Again, in the D/D group with rifampicin administered throughout, the treatment success was comparable among studies where therapy were fully supervised (90% (95% CI: 74-1.00) and not fully/unsupervised (90% (95% CI: 83-95) (table 2).
Publication bias
We evaluated publication bias through visual inspection of funnel plots based on standard error (Figures 4 -5) . We observed that they were not interpretable and is in keeping with the observation that visual inspection of funnel plots can misrepresent bias and be misleading as well [10, 17, 46] , we further examined publication bias using the Doi plot. The Doi plots for treatment Intermittent vs. daily TB regimens: a meta-analysis Page 9 Copyright © 2015 Marshfield Clinic Health System success for D/D regimens were more or less symmetrical suggesting no gross bias (figure 4). For I/I regimens, there was gross asymmetry for both success and default proportions with possible heterogeneity across the studies favouring more success but more default as well and thus low default proportions with these regimens are unlikely to have been influenced by under-reporting (Figures 4 and 5) .
Discussion
In this study of 27 studies involving EHRZ in the initial phase of TB treatment, administration of therapy intermittently (I/I) twice or three times a week rather than daily (D/D) was associated with similar treatment outcomes of success and failure (Table 1 and Indeed, intermittent regimens have been found to offer practical solutions to high pill burdens, inconvenience and intractable drug adverse reactions associated will daily TB therapies [1, 49] .
The trade-off however is with increase in relapse with I/I that is matched by the increase in default with D/D. The D/I regimen had a slightly lower default but relapse was still higher. This finding is supported by a review [6] that examined intermittent therapy of thrice weekly versus daily therapy in a single randomized trial [26] where intermittent therapy was administered and recurrence was 4 fold increased with intermittent therapy (non-significant) compared to the daily group but no conclusions were drawn. These observed differences in treatment relapse versus default rates were not reported by Menzies et al because they used pooled cumulative incidences, adjusted incidence rate ratios and risk differences only on outcomes of failure, relapse and acquired drug resistance and did not separate out rifampicin duration and intermittency of therapy [3] . In our case, we used proportions of successfully treated, failure, relapse and default as separate categories and pooled them simultaneously. Analyses were also done separately for regimens with rifampicin in all phases versus rifampicin in IP only. We believe that these results point towards the fact that I/I regimens possibly require a longer duration than 6 months to prevent relapses since a Twelve studies had no rifampicin in the CP and included two studies [19, 37] versus 15% (CI: 2-30). Thus these regimens are unsuccessful because subjects default rather than relapse. Menzies et al were not able to demonstrate this because they did not separate out duration of rifampicin from intensity (frequency) of therapy. These observed differences for short duration rifampicin based regimens which could therefore possibly be explained by increased default possibly due to Ethambutol related toxicity [51] .
There were some studies that appeared to be outliers in the forest plot (figure 2-3) but none of the studies gave any details. McGregor et al [24] report indicates that 24 defaulted but no reasons were given. Su et al [39] reported that only 51 out of 105 patients enrolled into the study completed the full course. Analysis of the study report indicates a possible poor patient management protocol that led to a high attrition rate and 33 defaulted. In addition to defaulters, 51.4% of the study participants never completed. Similarly, Nunn et al. [19] appeared as an outlier because 237 patients defaulted but again no reason was given except that they mention default rate were similar across all the three regimens they compared.
This meta-analysis had a number of limitations. Most studies that reported drug resistance did not uniformly provide elaborate information among their findings. The few that attempted to do this did not provide information in a standard manner to facilitate useful analysis that could yield generalizable results. Therefore, this study did not look at the effect of primary drug resistance on the outcomes neither did it look at acquired drug resistance. More still, although three trails incorporated in this meta-analysis included a few HIV sero-positive TB patients; this study was unable to determine their impact on the overall results. However, in a separate study involving HIV infected TB patients, intermittent TB therapy with rifampicin based regimens alone on a twice Intermittent vs. daily TB regimens: a meta-analysis Page 11 Copyright © 2015 Marshfield Clinic Health System weekly dosing schedule in the initial phase but not in the continuous phase, was associated with high risk of relapses and an increased risk of acquired rifampicin resistance [52] . Such studies were however given a lower quality score which mitigates this to some extent. Another major limitation was the fact that there were fewer studies done involving completely intermittent therapy thereby limiting the number of studies available for this analysis. However, follow up was satisfactory in all studies except in three where the follow up period was less than one year but this finding, is not expected to affect study results since the majority of studies had more than one year of follow up period. Again, these studies were given a lower quality score.
Conclusion
In conclusion, poor treatment compliance and adherence due to longer duration of therapy is linked to poor outcomes [53, 54] and thus to ensure improved treatment efficacy and adherence as well as compliance, we believe that there is a need to switch to treatment regimens containing rifampicin in both phases that are offered I/I while ensuring DOT (directly observed therapy)
among HIV sero-negative TB patients since they are associated with similar treatment success and failure and low default rates. However, relapse rates are higher and it is possible that this could be mitigated by a longer duration of more than six months therapy, but this needs to be further investigated urgently by future studies. Tables   Table 1: TB treatment outcomes (37 datasets from Adults with Newly diagnosed sputum smear positive pulmonary TB, with no cavitation and no abnormality in more than one lobe on plain CXR were eligible while those with concomitant Hypertension, DM, Epilepsy, immunodeficiency and serious forms of EPTB were excluded.
Year of publication
There were 28 females with mean age of 15 years and 39 males with mean age of 52 years. 13 patients were from Afghan and rest from Iran recruited from a health center
2EHRZ/4RH
All drugs were administered under DOT as daily Single doses All drugs were administered under DOT as daily Single doses [3] Africa and Asia
Multi-centre randomised controlled trial where allocation sequence was independently computer generated and supplied to participating centres in sealed envelopes.
Patients with at least two positive sputum smears for AFFBs, with no previous anti-TB chemotherapy for more than one month, with accessible addresses and those willing to undergo HIV testing were eligible. Ineligible were pregnant women, EPTB and psychiatric patients, the ill and those with concomitant disease (DM, Epilepsy, liver diseases, nephritis, peripheral neuritis, blood disorders, alcoholism) and patients with confirmed Rifampicin resistance Pre-treatment characteristics were broadly similar and median age was 28 years with 66% of patients being males and 13% of 881 tested being HIV positive. [6] Thailand Randomized controlled trial where 837 patients were assigned to receive TB treatment -2EHRZ/4RH by DOT or self-administration on basis of daily drug supply in 15 study sites TB patients with a positive sputum smear for AFBs. Ineligible were patients less than 15 years old, patients with previous history of treatment for TB for ˃ 1 month, known allergy to any of the drugs in treatment regimen, pregnancy, hepatic or renal failure patients.
Mean age was for DOT and selfsupervised was 45±17. The male: female ratio was 2.6:1 for DOT and 2.9:1 for self-supervised. Unemployed on DOT were 17 and 20 for self-supervised. All recruited from Zonal Government TB centers and hospitals TB centres
Selfadministered [7] Brazil, Philippines and Uganda Was data collected in the same way for all subjects in the study 
